SCHEMBL23834656

SCHEMBL23834656

NC(=O)c1cccc(F)c1OC(F)F

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.46
IRAK4 Q9NWZ3 1/20 0.41
CES2 O00748 3/20 0.40
CES1 P23141 3/20 0.40
MAPT P10636 2/20 0.40
BCHE P06276 1/20 0.40
HTT P42858 1/20 0.40
KMT2A Q03164 1/20 0.39
ALB P02768 1/20 0.38
KEAP1 Q14145 1/20 0.38
NFE2L2 Q16236 1/20 0.38
PBRM1 Q86U86 1/20 0.38
PARP1 P09874 1/20 0.38
KDM4E B2RXH2 1/20 0.37
HPGD P15428 1/20 0.37
TSHR P16473 1/20 0.37
HSD17B10 Q99714 1/20 0.37
KDR P35968 1/20 0.37
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12492897 0.84 ALB (0.52) ALDH1A1CES2CES1MAPTBCHE
SCHEMBL15689396 0.84 IRAK4 (0.42) ALDH1A1IRAK4MAPTKEAP1NFE2L2
SCHEMBL12569788 0.81 IRAK4 (0.44) ALDH1A1IRAK4HTTKEAP1NFE2L2
SCHEMBL12492132 0.80 ALDH1A1 (0.47) ALDH1A1MAPTKMT2AKDM4EHPGD
SCHEMBL28816656 0.80 IRAK4 (0.43) IRAK4MAPTHTTPARP1
SCHEMBL29493466 0.80 IRAK4 (0.43) IRAK4MAPTHTTPARP1
SCHEMBL6643313 0.79 CES2 (0.41) ALDH1A1IRAK4CES2CES1MAPT
SCHEMBL18415112 0.79 IRAK4 (0.41) ALDH1A1IRAK4MAPTHTTKMT2A
SCHEMBL12545966 0.79 IRAK4 (0.45) IRAK4HTTHPGDTSHRLMNA
SCHEMBL528652 0.79 LMNA (0.43) ALDH1A1IRAK4CES2CES1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4121421-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS Novartis AG (CH) 2023-01-25 EP claimed
WO-2021186324-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS NOVARTIS AG (CH) 2021-09-23 WO claimed
US-20240382457-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS NOVARTIS PHARMA AG (CH) 2024-11-21 US disclosed
US-12083101-B2 Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors NOVARTIS AG (CH) 2024-09-10 US disclosed
EP-4395769-A1 PHARMACEUTICAL COMBINATIONS COMPRISING A TEAD INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS Novartis AG (CH) 2024-07-10 EP disclosed
WO-2023031781-A1 PHARMACEUTICAL COMBINATIONS COMPRISING A TEAD INHIBITOR AND USES THEREOF FOR THE TREATMENT OF CANCERS NOVARTIS AG (CH) 2023-03-09 WO disclosed
EP-4121421-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS Novartis AG (CH) 2023-01-25 EP disclosed
WO-2021186324-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS NOVARTIS AG (CH) 2021-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12083101-B2 Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors YAP1, TEAD3, TEAD2 ALDH1A1 3440/4885IRAK4 4042/4885CES2 4433/4885
US-20240382457-A1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS YAP1, TEAD3, TEAD2 ALDH1A1 3440/4885IRAK4 4042/4885CES2 4433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.